This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: Biocryst Pharmaceuticals, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Rick McElheny: Innovator in Ophthalmic Therapies
Introduction
Rick McElheny is a notable inventor based in Alpharetta, GA (US). He has made significant contributions to the field of ophthalmic therapies, particularly in the treatment of ocular disorders. His innovative approach focuses on non-surgical methods to deliver therapeutic agents directly to the eye.
Latest Patents
Rick McElheny holds a patent for "Plasma kallikrein inhibitors and methods of use thereof in ocular disorders." This patent addresses the treatment of various ocular diseases and conditions through the non-surgical administration of a drug composition containing a plasma kallikrein inhibitor, such as avoralstat. The methods described in the patent include the delivery of the inhibitor to the suprachoroidal space (SCS) of the eye, showcasing a novel approach to ocular therapy.
Career Highlights
Throughout his career, Rick has worked with prominent companies in the pharmaceutical industry. He has been associated with Biocryst Pharmaceuticals, Inc. and Copernicus Therapeutics, Inc., where he has contributed to the development of innovative therapies. His work has focused on advancing treatment options for patients suffering from ocular disorders.
Collaborations
Rick has collaborated with various professionals in the field, including his coworker Viral Kansara. Their combined expertise has contributed to the advancement of ophthalmic therapies and the development of new treatment methodologies.
Conclusion
Rick McElheny is a pioneering inventor whose work in ophthalmic therapies has the potential to transform the treatment of ocular disorders. His innovative patent and career achievements reflect his commitment to improving patient outcomes through advanced therapeutic approaches.